This trial is active, not recruiting.

Condition hiv infection
Treatment raltegravir
Sponsor The University of Texas Health Science Center, Houston
Start date September 2014
End date December 2015
Trial size 256 participants
Trial identifier NCT02302950, HSC-MS-14-0559


Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective retrospective
minority women that picked up raltegravir at Thomas street Health Center 2013
raltegravir issentress
HIV therapy component

Primary Outcomes

Assess the efficacy of raltegravir in study participants by measuring CD4 count and viral load
time frame: 24 weeks of therapy

Secondary Outcomes

Capture data on concomitant conditions that may have led to participants switching to raltegravir from medical records (eg. Diabetes mellitus)
time frame: 24 weeks of therapy
Assess tolerability of raltegravir by capturing symptoms
time frame: 24 weeks of therapy

Eligibility Criteria

Female participants at least 18 years old.

Inclusion Criteria: 1. HIV-infected women who picked up raltegravir in the year 2013 at Thomas Street Health Center. 2. Minority women -Black/African American, Hispanic/Latino Exclusion Criteria: - n/a

Additional Information

Official title A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by The University of Texas Health Science Center, Houston.